{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:43:59Z","timestamp":1790336639216,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41433-025-03813-2","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T11:07:05Z","timestamp":1746270425000},"page":"2159-2163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Aflibercept 2\u2009mg biosimilar (Tyalia)\u2014real-world experience from IRAN (ATRIA study)"],"prefix":"10.1038","volume":"39","author":[{"given":"Sahar","family":"Avadzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8550-9791","authenticated-orcid":false,"given":"Ashish","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mehdi","family":"Parvaresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5221-1844","authenticated-orcid":false,"given":"Khalil","family":"Ghasemi Falavarjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"International Retina Biosimilar Study Group (Inter BIOS Group)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baruch D.","family":"Kuppermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Loewenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl D.","family":"Regillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Vazquez-Alfageme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikulaa","family":"Parachuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seemantini","family":"Ayachit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitaranjan","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debdulal","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alay","family":"Banker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kourous A.","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad M.","family":"Khanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Querques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eeng\u00fcl","family":"\u00d6zdek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kodjikian","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Bilgic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Baumal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Holekemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Tufail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Yannuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Corradetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assaf","family":"Hilely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Rachitskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunde","family":"Peto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian WM","family":"Wintergerst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Sarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Parolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithvi","family":"Mruthyunjaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan Dong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana V.","family":"DO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearse A.","family":"Keane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanth","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Eichenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilraj S.","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"March","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Zinkernagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Ueda-Consolvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichiro","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Joon","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Sagong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Seungkyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,3]]},"reference":[{"key":"3813_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01554-2","volume":"20","author":"RP Finger","year":"2020","unstructured":"Finger RP, Daien V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P, et al. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems. BMC Ophthalmol. 2020;20:294.","journal-title":"BMC Ophthalmol"},{"key":"3813_CR2","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1097\/IAE.0000000000003626","volume":"42","author":"PK Kaiser","year":"2022","unstructured":"Kaiser PK, Schmitz-Valckenberg MS, Holz FG. Anti-vascular endothelial growth factor biosimilars in ophthalmology. Retina 2022;42:2243\u201350.","journal-title":"Retina"},{"key":"3813_CR3","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.4103\/ijo.IJO_1866_19","volume":"68","author":"A Kelkar","year":"2020","unstructured":"Kelkar A, Webers C, Shetty R, Kelkar J, Labhsetwar N, Pandit A, et al. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema. Indian J Ophthalmol. 2020;68:2143\u20137.","journal-title":"Indian J Ophthalmol"},{"key":"3813_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ajo.2020.11.017","volume":"224","author":"A Sharma","year":"2021","unstructured":"Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD, Loewenstein A. Biosimilars for retinal diseases: an update. Am J Ophthalmol. 2021;224:36\u201342.","journal-title":"Am J Ophthalmol"},{"key":"3813_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41433-022-02246-5","volume":"37","author":"A Sharma","year":"2023","unstructured":"Sharma A, Kondo M, Iwahashi C, Parachuri N, Kumar N, Bandello F, et al. Approved biosimilar ranibizumab-a global update. Eye (Lond). 2023;37:200\u20132.","journal-title":"Eye (Lond)"},{"key":"3813_CR6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/14712598.2023.2239706","volume":"23","author":"A Sharma","year":"2023","unstructured":"Sharma A, Kumar N, Parachuri N, Loewenstein A, Bandello F, Kuppermann BD. Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South Asia. Expert Opin Biol Ther. 2023;23:689\u201392.","journal-title":"Expert Opin Biol Ther"},{"key":"3813_CR7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1080\/14712598.2023.2176218","volume":"23","author":"A Sharma","year":"2023","unstructured":"Sharma A, Holz FG, Regillo CD, Freund KB, Sarraf D, Khanani AM, et al. Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey). Expert Opin Biol Ther. 2023;23:851\u20139.","journal-title":"Expert Opin Biol Ther"},{"key":"3813_CR8","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1038\/s41433-024-03284-x","volume":"38","author":"A Sharma","year":"2024","unstructured":"Sharma A, Kaiser PK, Tadayoni R, Holz FG, Nicholson L, Vazquez-Alfageme C, et al. Anti-VEGF Biosimilars for Retinal Diseases Survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI). Eye (Lond). 2024;38:3392\u201395.","journal-title":"Eye (Lond)"},{"key":"3813_CR9","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1038\/s41433-024-03220-z","volume":"38","author":"T Ueda-Consolvo","year":"2024","unstructured":"Ueda-Consolvo T, Ishida M, Nakamura T, Yanagisawa S, Tsuboi K, Wakabayashi T, et al. Biosimilar ranibizumab (BS1) - early experience from Japan (BRIJ study). Eye (Lond). 2024;38:3193\u201396.","journal-title":"Eye (Lond)"},{"key":"3813_CR10","doi-asserted-by":"publisher","unstructured":"Sharma A, Holz FG, Kumar N, Sarraf D, Ayachit S, Mishra C, et al. Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study. J Vitreoretin Dis. 2025;24741264251322213 https:\/\/doi.org\/10.1177\/24741264251322213.","DOI":"10.1177\/24741264251322213"},{"key":"3813_CR11","unstructured":"FDA Approves Amgen\u2019s Pavblu\u2122 as Fifth Aflibercept Biosimilar. https:\/\/www.lexology.com\/library\/detail.aspx?g=e930ee60-d2a7-4e8c-9d41-42adb9897a7f#:~:text=Pavblu%E2%84%A2%20is%20the%20fifth,Yesafili%E2%84%A2%20(May%202024). Accessed November 19, 2024"},{"key":"3813_CR12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.oret.2024.02.012","volume":"8","author":"R Karkhaneh","year":"2024","unstructured":"Karkhaneh R, Faghihi H, Riazi-Esfahani H, Abrishami M, Bazvand F, Ebrahimiadib N, et al. Evaluating the efficacy and safety of aflibercept biosimilar (P041) compared with originator product in patients with neovascular age-related macular degeneration. Ophthalmol Retin. 2024;8:744\u201353.","journal-title":"Ophthalmol Retin"},{"key":"3813_CR13","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/s41433-019-0434-y","volume":"33","author":"A Sharma","year":"2019","unstructured":"Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Biotherapeutics and immunogenicity: ophthalmic perspective. Eye (Lond). 2019;33:1359\u201361.","journal-title":"Eye (Lond)"},{"key":"3813_CR14","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/s41433-020-0853-9","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma A, Kumar N, Parachuri N, Sharma R, Bandello F, Kuppermann BD, et al. Brolucizumab and immunogenicity. Eye (Lond). 2020;34:1726\u20138.","journal-title":"Eye (Lond)"},{"key":"3813_CR15","unstructured":"FDA rejects first DARPin https:\/\/www.nature.com\/articles\/d41573-020-00127-8. Accessed November 19, 2024."},{"key":"3813_CR16","unstructured":"ASRS reports six cases of occlusive retinal vasculitis linked to pegcetacoplan injection. https:\/\/www.ophthalmologytimes.com\/view\/asrs-reports-six-cases-of-occlusive-retinal-vasculitis-linked-to-pegcetacoplan-injection. Accessed November 19, 2024."},{"key":"3813_CR17","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41433-019-0636-3","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Ophthalmic biosimilars and biologics-role of endotoxins. Eye (Lond). 2020;34:614\u20135.","journal-title":"Eye (Lond)"},{"key":"3813_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000488602","volume":"241","author":"S Sharma","year":"2019","unstructured":"Sharma S, Khan MA, Chaturvedi A, RE-ENACT Study Investigators Group. Real-Life clinical effectiveness of Razumab\u00ae (the world\u2019s first biosimilar of ranibizumab) in retinal vein occlusion: a subgroup analysis of the pooled retrospective RE-ENACT study. Ophthalmologica. 2019;241:24\u201331.","journal-title":"Ophthalmologica"},{"key":"3813_CR19","first-page":"368","volume":"6","author":"S Sharma","year":"2018","unstructured":"Sharma S, Khan MA, Chaturvedi A, RE-ENACT Study Investigators Group. Real life clinical effectiveness of Razumab\u00ae (world\u2019s first biosimilar ranibizumab) in wet age-related macular degeneration: a subgroup analysis of pooled retrospective RE-ENACT study. Int J Ophthalmol Eye Res. 2018;6:368\u201373.","journal-title":"Int J Ophthalmol Eye Res"},{"key":"3813_CR20","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41433-019-0745-z","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma A, Hafeez Faridi M, Kumar N, Parachuri N, Sharma R, Kuppermann BD, et al. Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data. Eye (Lond). 2020;34:1008\u20139.","journal-title":"Eye (Lond)"},{"key":"3813_CR21","doi-asserted-by":"publisher","unstructured":"Sharma A, Loewenstein A, Parachuri N, Kumar N, Kuppermann BD. Biosimilar to biosimilar. Anti-VEGF switching for retinal diseases. J VitreoRetinal Dis. 2023;0(0). https:\/\/doi.org\/10.1177\/24741264231202080.","DOI":"10.1177\/24741264231202080"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03813-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03813-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03813-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T12:46:51Z","timestamp":1757162811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03813-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3813"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03813-2","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,3]]},"assertion":[{"value":"3 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KGF: Consultant for CinnaGen. Ashish Sharma: Consultant for Bayer, Lupin, Novartis, Allergan, Roche and Intas. SA and MMP: None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}